This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 1 of 1 for:    502-201
Previous Study | Return to List | Next Study

A Study of ARRY-502 in Patients With Persistent Asthma

This study has been completed.
Information provided by (Responsible Party):
Array BioPharma Identifier:
First received: March 21, 2012
Last updated: June 6, 2013
Last verified: June 2013
This is a Phase 2 study, involving a 6-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-502 in treating mild to moderate persistent asthma, and to further evaluate the safety of the drug. Approximately 180 patients from the US will be enrolled in this study.

Condition Intervention Phase
Asthma Drug: ARRY-502, CRTh2 antagonist; oral Drug: Placebo; oral Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Further study details as provided by Array BioPharma:

Primary Outcome Measures:
  • Assess the efficacy of the study drug (versus placebo) in terms of prebronchodilator forced expiratory volume in 1 second (FEV1). [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, vital signs and electrocardiograms. [ Time Frame: 6 weeks ]
  • Measure the exposure of study drug in terms of plasma concentrations. [ Time Frame: 6 weeks ]
  • Assess the effect of study drug on asthma control in terms of Asthma Control Questionnaire (ACQ) score, the number of symptom-free days and the number of weekly short-acting beta (ß) 2 agonist (SABA) metered dose inhaler (MDI) actuations. [ Time Frame: 6 weeks ]
  • Assess the effect of study drug on respiratory function in terms of FEV1, forced vital capacity (FVC), forced expiratory flow (FEF) and peak expiratory flow (PEF). [ Time Frame: 6 weeks ]

Enrollment: 184
Study Start Date: March 2012
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ARRY-502 Drug: ARRY-502, CRTh2 antagonist; oral
multiple dose, single schedule
Placebo Comparator: Placebo Drug: Placebo; oral
matching placebo


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Documented history of bronchial asthma diagnosed at least 6 months prior to study start and prior to the age of 40 years.
  • Body mass index (BMI) of 18 to 35 inclusive.
  • An ACQ score of ≥ 1.5 at specified time points prior to first dose of study drug.
  • A best prebronchodilator FEV1 of 60% to 85% of the predicted normal value and a change in best postbronchodilator FEV1 of ≥ 12% and ≥ 200 mL at specified time points prior to first dose of study drug.
  • Additional criteria exist.

Key Exclusion Criteria:

  • Evidence of aspirin-sensitive asthma.
  • Pre-existing lung disease other than asthma.
  • Clinically significant dermatologic, hematological, renal, endocrine, pulmonary (other than asthma), gastrointestinal, cardiovascular, hepatic, neurologic, ophthalmologic, musculoskeletal or immunologic disease (excepting allergic disease and asthma) that is uncontrolled despite treatment or is likely in the opinion of the Investigator to require a change in therapy during the study.
  • Patients with any current or past history of cancer within 5 years prior to study start except for treated basal cell or squamous cell carcinomas of the skin, ductal carcinoma in situ of the breast or cervical carcinomas in situ.
  • Any history of serious illness requiring hospitalization within 6 months prior to study start.
  • Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or active hepatitis C.
  • A positive test for drugs or alcohol, unless the positive drug screen is associated with a prescribed medication and is approved by the Medical Monitor.
  • Smoking (tobacco or marijuana) within 6 months prior to study start and/or a smoking history of > 10 packs/year.
  • Blood donation of ≥ 1 pint (473 mL) within 8 weeks prior to the first dose of study drug.
  • Previous treatment with ARRY-502.
  • Additional criteria exist.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01561690

  Show 43 Study Locations
Sponsors and Collaborators
Array BioPharma
  More Information

Responsible Party: Array BioPharma Identifier: NCT01561690     History of Changes
Other Study ID Numbers: ARRAY-502-201
Study First Received: March 21, 2012
Last Updated: June 6, 2013

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on September 21, 2017